Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Net Income (2016 - 2025)

Standard Biotools (LAB) has disclosed Net Income for 16 consecutive years, with -$3.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income rose 40.18% to -$3.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$112.8 million, a 130.54% decrease, with the full-year FY2024 number at -$138.9 million, down 237.45% from a year prior.
  • Net Income was -$3.0 million for Q3 2025 at Standard Biotools, up from -$17.7 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $153.2 million in Q4 2022 to a low of -$76.3 million in Q1 2022.
  • A 5-year average of -$15.4 million and a median of -$17.7 million in 2025 define the central range for Net Income.
  • Peak YoY movement for Net Income: skyrocketed 1724.73% in 2022, then crashed 532.8% in 2024.
  • Standard Biotools' Net Income stood at -$9.4 million in 2021, then surged by 1724.73% to $153.2 million in 2022, then plummeted by 91.05% to $13.7 million in 2023, then plummeted by 532.8% to -$59.3 million in 2024, then skyrocketed by 94.94% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Net Income are -$3.0 million (Q3 2025), -$17.7 million (Q2 2025), and -$32.8 million (Q1 2025).